Systems biology of IL-6, IL-12 family cytokines

Cytokine and Growth Factor Reviews

Volumn 26, Issue 5, 2015, Pages 595-602

  Dittrich, Anna ^a   Hessenkemper, Wiebke ^a   Schaper, Fred ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

IL 6 type cytokines; Mathematical modeling; Quantitative analyses; Systems biology

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; SCATTER FACTOR; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; IL6 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE RELEASE; DRUG TARGETING; EMBRYONIC STEM CELL; HUMAN; INFLAMMATION; NONHUMAN; PHARMACODYNAMICS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; IMMUNOLOGY; PROCEDURES; SYSTEMS BIOLOGY;

ANIMALS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-6; SYSTEMS BIOLOGY;

EID: 84941902482     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.07.002     Document Type: Short Survey

References (90)

1. Bruggeman F.J., Westerhoff H.V. The nature of systems biology. Trends Microbiol. 2007, 15:45-50.
2. Cho K.H., Wolkenhauer O. Analysis and modelling of signal transduction pathways in systems biology. Biochem. Soc. Trans. 2003, 31:1503-1509.
3. Pfeifer A.C., Timmer J., Klingmüller U. Systems biology of JAK/STAT signalling. Essays Biochem. 2008, 45:109-120.
4. Wolkenhauer O. Systems biology: the reincarnation of systems theory applied in biology?. Brief Bioinf. 2001, 2:258-270.
5. Kitano H. Systems biology: a brief overview. Science 2002, 295:1662-1664.
6. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
7. Eulenfeld R., Dittrich A., Khouri C., et al. Interleukin-6 signalling: more than Jaks and STATs. Eur. J. Cell Biol. 2012, 91:486-495.
8. Swameye I., Müller T.G., Timmer J., Sandra O., Klingmüller U. Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1028-1033.
9. Raia V., Schilling M., Böhm M., et al. Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets. Cancer Res. 2011, 71:693-704.
10. Vera J., Rateitschak K., Lange F., Kossow C., Wolkenhauer O., Jaster R. Systems biology of JAK-STAT signalling in human malignancies. Prog. Biophys. Mol. Biol. 2011, 106:426-434.
11. Garbers C., Hermanns H.M., Schaper F., et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012, 23:85-97.
12. Aldridge B.B., Burke J.M., Lauffenburger D.A., Sorger P.K. Physicochemical modelling of cell signalling pathways. Nat. Cell Biol. 2006, 8:1195-1203.
13. Loewer A., Lahav G. We are all individuals: causes and consequences of non-genetic heterogeneity in mammalian cells. Curr. Opin. Genet. Dev. 2011, 21:753-758.
14. Baumann H., Isseroff H., Latimer J.J., Jahreis G.P. Phorbol ester modulates interleukin 6- and interleukin 1-regulated expression of acute phase plasma proteins in hepatoma cells. J. Biol. Chem. 1988, 263:17390-17396.
15. Dittrich A., Quaiser T., Khouri C., Görtz D., Mönnigmann M., Schaper F. Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling. Mol. Biosyst. 2012, 8:2119-2134.
16. Pietzko D., Zohlnhöfer D., Graeve L., et al. The hepatic interleukin-6 receptor, Studies on its structure and regulation by phorbol 12-myristate 13-acetate-dexamethasone. J. Biol. Chem. 1993, 268:4250-4258.
17. Klingmüller U., Bauer A., Bohl S., et al. Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways. Syst. Biol. (Stevenage) 2006, 153:433-447.
18. Schoeberl B., Eichler-Jonsson C., Gilles E.D., Muller G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat. Biotechnol. 2002, 20:370-375.
19. Altan-Bonnet G., Germain R.N. Modeling T cell antigen discrimination based on feedback control of digital ERK responses. PLoS Biol. 2005, 3:e356.
20. Siewert E., Müller-Esterl W., Starr R., Heinrich P.C., Schaper F. Different protein turnover of interleukin-6-type cytokine signalling components. Eur. J. Biochem. 1999, 265:251-257.
21. Schilling M., Maiwald T., Bohl S., et al. Quantitative data generation for systems biology: the impact of randomisation, calibrators and normalisers. Syst. Biol. (Stevenage) 2005, 152:193-200.
22. Korf U., Derdak S., Tresch A., et al. Quantitative protein microarrays for time-resolved measurements of protein phosphorylation. Proteomics 2008, 8:4603-4612.
23. Hahn B., Böhm M., Raia V., et al. One-source peptide/phosphopeptide standards for accurate phosphorylation degree determination. Proteomics 2011, 11:490-494.
24. Maiwald T., Kreutz C., Pfeifer A.C., Bohl S., Klingmüller U., Timmer J. Dynamic pathway modeling: feasibility analysis and optimal experimental design. Ann. N.Y. Acad. Sci. 2007, 1115:212-220.
25. Gerhartz C., Dittrich E., Stoyan T., et al. Biosynthesis and half-life of the interleukin-6 receptor and its signal transducer gp130. Eur. J. Biochem. 1994, 223:265-274.
26. Dittrich A., Khouri C., Sackett S.D., et al. Glucocorticoids increase interleukin-6-dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3 feedback inhibitor. Hepatology 2012, 55:256-266.
27. Legewie S., Herzel H., Westerhoff H.V., Blüthgen N. Recurrent design patterns in the feedback regulation of the mammalian signalling network. Mol. Syst. Biol. 2008, 4:190.
28. Lehmann U., Sommer U., Smyczek T., et al. Determinants governing the potency of STAT3 activation via the individual STAT3-recruiting motifs of gp130. Cell Signal. 2006, 18:40-49.
29. Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990, 63:1149-1157.
30. Honda M., Yamamoto S., Cheng M., et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J. Immunol. 1992, 148:2175-2180.
31. Weiergraber O., Hemmann U., Küster A., et al. Soluble human interleukin-6 receptor, expression in insect cells, purification and characterization. Eur. J. Biochem. 1995, 234:661-669.
32. De Souza D., Fabri L.J., Nash A., Hilton D.J., Nicola N.A., Baca M. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 2002, 41:9229-9236.
33. Lehmann U., Schmitz J., Weissenbach M., et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J. Biol. Chem. 2003, 278:661-671.
34. Wenta N., Strauss H., Meyer S., Vinkemeier U. Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9238-9243.
35. Quaiser T., Mönnigmann M. Systematic identifiability testing for unambiguous mechanistic modeling-application to JAK-STAT, MAP kinase, and NF-kappaB signaling pathway models. BMC Syst. Biol. 2009, 3:50.
36. Raue A., Karlsson J., Saccomani M.P., Jirstrand M., Timmer J. Comparison of approaches for parameter identifiability analysis of biological systems. Bioinformatics 2014, 30:1440-1448.
37. Streif S., Savchenko A., Rumschinski P., Borchers S., Findeisen R. ADMIT: a toolbox for guaranteed model invalidation, estimation and qualitative-quantitative modeling. Bioinformatics 2012, 28:1290-1291.
38. Mathew S., Bartels J., Banerjee I., Vodovotz Y. Global sensitivity analysis of a mathematical model of acute inflammation identifies nonlinear dependence of cumulative tissue damage on host interleukin-6 responses. J. Theor. Biol. 2014, 358:132-148.
39. Torres A., Bentley T., Bartels J., et al. Mathematical modeling of posthemorrhage inflammation in mice: studies using a novel, computer-controlled, closed-loop hemorrhage apparatus. Shock 2009, 32:172-178.
40. Blätke M.A., Dittrich A., Rohr C., Heiner M., Schaper F., Marwan W. JAK/STAT signalling-an executable model assembled from molecule-centred modules demonstrating a module-oriented database concept for systems and synthetic biology. Mol. Biosyst. 2013, 9:1290-1307.
41. Guerriero M.L., Dudka A., Underhill-Day N., Heath J.K., Priami C. Narrative-based computational modelling of the Gp130/JAK/STAT signalling pathway. BMC Syst. Biol. 2009, 3:40.
42. Singh A., Jayaraman A., Hahn J. Modeling regulatory mechanisms in IL-6 signal transduction in hepatocytes. Biotechnol. Bioeng. 2006, 95:850-862.
43. Theis F.J., Bohl S., Klingmüller U. Theoretical analysis of time-to-peak responses in biological reaction networks. Bull. Math. Biol. 2011, 73:978-1003.
44. Yamada S., Shiono S., Joo A., Yoshimura A. Control mechanism of JAK/STAT signal transduction pathway. FEBS Lett. 2003, 534:190-196.
45. Moya C., Huang Z., Cheng P., Jayaraman A., Hahn J. Investigation of IL-6 and IL-10 signalling via mathematical modelling. IET Syst. Biol. 2011, 5:15.
46. Chu Y., Jayaraman A., Hahn J. Parameter sensitivity analysis of IL-6 signalling pathways. IET Syst. Biol. 2007, 1:342-352.
47. McArdle A., Kruger U., Hahn J. Multivariate statistical analysis applied to an IL6 signal transduction model in hepatocytes. Stat. Med. 2009, 28:2401-2434.
48. Fischer P., Lehmann U., Sobota R.M., et al. The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem. J. 2004, 378:449-460.
49. Wormald S., Zhang J.G., Krebs D.L., et al. The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J. Biol. Chem. 2006, 281:11135-11143.
50. Niemand C., Nimmesgern A., Haan S., et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J. Immunol. 2003, 170:3263-3272.
51. Yasukawa H., Ohishi M., Mori H., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 2003, 4:551-556.
52. Braun D.A., Fribourg M., Sealfon S.C. Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation. J. Biol. Chem. 2013, 288:2986-2993.
53. Jayaraman A., Yarmush M.L., Roth C.M. Dynamics of gene expression in rat hepatocytes under stress. Metab. Eng. 2000, 2:239-251.
54. Mahdavi A., Davey R.E., Bhola P., Yin T., Zandstra P.W. Sensitivity analysis of intracellular signaling pathway kinetics predicts targets for stem cell fate control. PLoS Comput. Biol. 2007, 3:e130.
55. Quaiser T., Dittrich A., Schaper F., Mönnigmann M. A simple work flow for biologically inspired model reduction-application to early JAK-STAT signaling. BMC Syst. Biol. 2011, 5:30.
56. Lu W., Shen K., Cole P.A. Chemical dissection of the effects of tyrosine phosphorylation of SHP-2. Biochemistry 2003, 42:5461-5468.
57. Lu W., Gong D., Bar-Sagi D., Cole P.A. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol. Cell 2001, 8:759-769.
58. Barua D., Faeder J.R., Haugh J.M. Structure-based kinetic models of modular signaling protein function: focus on Shp2. Biophys. J. 2007, 92:2290-2300.
59. Stein-Gerlach M., Kharitonenkov A., Vogel W., Ali S., Ullrich A. Protein-tyrosine phosphatase 1D modulates its own state of tyrosine phosphorylation. J. Biol. Chem. 1995, 270:24635-24637.
60. Scheller J., Garbers C., Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin. Immunol. 2014, 26:2-12.
61. Garbers C., Thaiss W., Jones G.W., et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J. Biol. Chem. 2011, 286:42959-42970.
62. Tanaka T., Narazaki M., Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 2012, 52:199-219.
63. Frey N., Grange S., Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J. Clin. Pharmacol. 2010, 50:754-766.
64. Kretsos K., Jullion A., Zamacona M., et al. Model-based optimal design and execution of the first-inpatient trial of the anti-IL-6, Olokizumab. CPT Pharmacometrics Syst. Pharmacol. 2014, 3:e119.
65. Dwivedi G., Fitz L., Hegen M., et al. A multiscale model of interleukin-6-mediated immune regulation in Crohn's disease and its application in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2014, 3:e89.
66. Chaudhry M.A., Bowen B.D., Eaves C.J., Piret J.M. Empirical models of the proliferative response of cytokine-dependent hematopoietic cell lines. Biotechnol. Bioeng. 2004, 88:348-358.
67. Tang Y., Tian X.C. JAK-STAT3 and somatic cell reprogramming. JAKSTAT 2013, 2:e24935.
68. Xu H., Ang Y.S., Sevilla A., Lemischka I.R., Ma'ayan A. Construction and validation of a regulatory network for pluripotency and self-renewal of mouse embryonic stem cells. PLoS Comput. Biol. 2014, 10:e1003777.
69. Peterson H., Abu Dawud R., Garg A., et al. Qualitative modeling identifies IL-11 as a novel regulator in maintaining self-renewal in human pluripotent stem cells. Front. Physiol. 2013, 4:303.
70. Huard J., Mueller S., Gilles E.D., Klingmüller U., Klamt S. An integrative model links multiple inputs and signaling pathways to the onset of DNA synthesis in hepatocytes. FEBS J. 2012, 279:3290-3313.
71. Siegel P.M., Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 2003, 3:807-821.
72. Ryll A., Samaga R., Schaper F., Alexopoulos L.G., Klamt S. Large-scale network models of IL-1 and IL-6 signalling and their hepatocellular specification. Mol. Biosyst. 2011, 7:3253-3270.
73. Xue X., Xia W., Wenzhong H. A modeled dynamic regulatory network of NF-kappaB and IL-6 mediated by miRNA. Biosystems 2013, 114:214-218.
74. Marquez R.T., Wendlandt E., Galle C.S., Keck K., McCaffrey A.P. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G535-G541.
75. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39:493-506.
76. Rowan A.D., Koshy P.J., Shingleton W.D., et al. Synergistic effects of glycoprotein 130 binding cytokines in combination with interleukin-1 on cartilage collagen breakdown. Arthritis Rheum. 2001, 44:1620-1632.
77. Proctor C.J., Macdonald C., Milner J.M., Rowan A.D., Cawston T.E. A computer simulation approach to assessing therapeutic intervention points for the prevention of cytokine-induced cartilage breakdown. Arthritis Rheumatol. 2014, 66:979-989.
78. Andrews N.C. Disorders of iron metabolism. N. Engl. J. Med. 1999, 341:1986-1995.
79. Casanovas G., Mleczko-Sanecka K., Altamura S., Hentze M.W., Muckenthaler M.U. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J. Mol. Med. (Berl.) 2009, 87:471-480.
80. Wrighting D.M., Andrews N.C. Interleukin-6 induces hepcidin expression through STAT3. Blood 2006, 108:3204-3209.
81. Casanovas G., Banerji A., d'Alessio F., Muckenthaler M.U., Legewie S. A multi-scale model of hepcidin promoter regulation reveals factors controlling systemic iron homeostasis. PLoS Comput. Biol. 2014, 10:e1003421.
82. Inoue H., Ogawa W., Ozaki M., et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 2004, 10:168-174.
83. Rahman S.M., Schroeder-Gloeckler J.M., Janssen R.C., et al. CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis. Hepatology 2007, 45:1108-1117.
84. den Boer M.A., Voshol P.J., Schroder-van der Elst J.P., et al. Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. Endocrinology 2006, 147:4553-4558.
85. Qi Y.F., Huang Y.X., Wang H.Y., et al. Elucidating the crosstalk mechanism between IFN-gamma and IL-6 via mathematical modelling. BMC Bioinform. 2013, 14:41.
86. Costa-Pereira A.P., Tininini S., Strobl B., et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:8043-8047.
87. Ho H.H., Ivashkiv L.B. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 2006, 281:14111-14118.
88. Gerhartz C., Heesel B., Sasse J., et al. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J. Biol. Chem. 1996, 271:12991-12998.
89. Rudolph N., Meyer T., Franzen K., Garbers C., Schaper F., Streif S., Dittrich A., Findeisen R. A two-level approach for fusing early signaling events and long term cellular resonses. Proc. Int. Symp. Adv. Control Chem. Processes (ADCHEM) 2015, 1229-1234.
90. Schaper F., Rose-John S. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 2015, 26:475-487.